JATT II Acquisition Corp (JATT) is a Blank Checks company listed on NASDAQ. There were no new wire items for JATT in the last 30 days. The most recent was published Aug 27, 2026.
News · 26 weeks140%
2026-05-102026-11-01
Mix990d
- Other6(67%)
- Offering2(22%)
- SEC Filings1(11%)
Latest news
25 items- PRJATT III Acquisition Corp Announces Closing of $69,000,000 Initial Public OfferingWESTFIELD, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- JATT III Acquisition Corp (the "Company") announced the closing of its initial public offering of 6,900,000 ordinary shares at an offering price of $10.00 per ordinary share on August 27, 2026, which includes 900,000 additional ordinary shares issued pursuant to the full exercise of the underwriters’ over-allotment option. Total gross proceeds from the offering were $69,000,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The ordinary shares began trading on the Nasdaq Global Market ("NASDAQ") under the ticker symbol "JTTT" on August 26, 2026. Guggenheim Securities, LLC acted
- PRJATT III Acquisition Corp Announces Pricing of $60,000,000 Initial Public OfferingWESTFIELD, N. J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- JATT III Acquisition Corp (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share. The ordinary shares are expected to trade on the Nasdaq Capital Market ("NASDAQ") under the ticker symbol "JTTT" beginning August 26, 2026. The offering is expected to close on August 27, 2026, subject to customary closing conditions. Guggenheim Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to pu
- SECSEC Form SCHEDULE 13G filed by JATT II Acquisition CorpSCHEDULE 13G - JATT II Acquisition Corp. (0002112446) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by JATT II Acquisition CorpSCHEDULE 13G/A - JATT II Acquisition Corp. (0002112446) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by JATT II Acquisition CorpSCHEDULE 13G/A - JATT II Acquisition Corp. (0002112446) (Subject)
- SECSEC Form SCHEDULE 13G filed by JATT II Acquisition CorpSCHEDULE 13G - JATT II Acquisition Corp. (0002112446) (Subject)
- SECSEC Form SCHEDULE 13G filed by JATT II Acquisition CorpSCHEDULE 13G - JATT II Acquisition Corp. (0002112446) (Subject)
- SECSEC Form SCHEDULE 13G filed by JATT II Acquisition CorpSCHEDULE 13G - JATT II Acquisition Corp. (0002112446) (Subject)
- SECSEC Form 10-Q filed by JATT II Acquisition Corp10-Q - JATT II Acquisition Corp. (0002112446) (Filer)
- INSIDERChief Executive Officer Sidhu Someit disposed of 225,000 units of Ordinary Shares (SEC Form 4)4 - JATT II Acquisition Corp. (0002112446) (Issuer)
- INSIDERLarge owner Jatt Ventures Ii L.P. disposed of 225,000 units of Ordinary Shares (SEC Form 4)4 - JATT II Acquisition Corp. (0002112446) (Issuer)
- SECJATT II Acquisition Corp filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - JATT II Acquisition Corp. (0002112446) (Filer)
- PRTalawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I DiseasesOversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined company at closing anticipated to fund TALA-125 through a Phase 2b proof-of-concept study data readout in the second half of 2028Talawar, the first company formed to develop and commercialize assets discovered by Khanda Therapeutics, L.P. ("Khanda"), is developing TALA-125, a novel anti-IL-13 × anti-IL-18 bispecific antibody for atopic dermatitis, with clinical entry expected in 1Q 2027Leadership team includes industry veterans, CEO Marc Schegerin, MD, MBA and CMO Fabio Nunes, MD, MMSc, with Praveen Tipirneni, MD, MBA joining the boardNEW YORK and WESTFIELD, N.J., June 29,
- SECSEC Form 10-Q filed by JATT II Acquisition Corp10-Q - JATT II Acquisition Corp. (0002112446) (Filer)
- SECSEC Form SCHEDULE 13G filed by JATT II Acquisition CorpSCHEDULE 13G - JATT II Acquisition Corp. (0002112446) (Subject)
- SECJATT II Acquisition Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - JATT II Acquisition Corp. (0002112446) (Filer)
- SECSEC Form SCHEDULE 13G filed by JATT II Acquisition CorpSCHEDULE 13G - JATT II Acquisition Corp. (0002112446) (Subject)
- SECSEC Form SCHEDULE 13G filed by JATT II Acquisition CorpSCHEDULE 13G - JATT II Acquisition Corp. (0002112446) (Subject)
- PRJATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public OfferingWESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the "Company") announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share on April 20, 2026. Total gross proceeds from the offering were $60,000,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The ordinary shares began trading on the Nasdaq Global Market ("NASDAQ") under the ticker symbol "JATT" on April 17, 2026. Guggenheim Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to purchase up to 900,000 additional ordi
- PRJATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public OfferingWESTFIELD, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share. The ordinary shares are expected to trade on the Nasdaq Global Market ("NASDAQ") under the ticker symbol "JATT" beginning April 17, 2026. The offering is expected to close on April 20, 2026, subject to customary closing conditions. Guggenheim Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to purcha
- 13D/GSEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
- 13D/GSEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
- 13D/GSEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
- 13D/GSEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
- 13D/GSEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)SC 13G/A - Zura Bio Ltd (0001855644) (Subject)
JATT FAQ
7 questionsWhat does JATT II Acquisition Corp do?
JATT Acquisition Corp intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to focus on businesses primarily operating in the life sciences sector. The company was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.What is the latest news on JATT?
Quantisnow has not tracked any new filings, ratings or press releases for JATT in the last 30 days. The most recent wire item was published on August 27, 2026.Where does JATT stock trade?
JATT II Acquisition Corp (JATT) is listed on NASDAQ.What sector and industry is JATT in?
JATT II Acquisition Corp operates in the Finance sector, Blank Checks industry.When did JATT II Acquisition Corp go public?
JATT II Acquisition Corp (JATT) completed its IPO in 2026.What companies are similar to JATT?
Notable peers in the same industry include TACO (Berto Acquisition Corp.), PRE (Prenetics Global Limited), ILLU (Illumination Acquisition Corp I), OXSQ (Oxford Square Capital Corp.), INV (Innventure Inc.). Compare JATT side-by-side with any of them on Quantisnow.How can I track JATT on Quantisnow?
Quantisnow aggregates JATT II Acquisition Corp's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JATT to receive live email and push alerts on every new disclosure.